Related Experiment Video
Updated: Dec 25, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its
Shuai Yuan1, Ang Lin2, Qi-Qiang He3
1Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Insights
Interleukin-6 (IL-6) inhibition may prevent cardiovascular diseases like coronary artery disease (CAD) and atrial fibrillation (AF). However, increased Interleukin-1 receptor antagonist (IL-1ra) levels may raise the risk for CAD and cardioembolic stroke.
Area of Science:
- Genetics
- Immunology
- Cardiovascular Medicine
Background:
- The precise role of interleukins (ILs) in cardiovascular disease pathogenesis remains unclear.
- Investigating the causal links between circulating ILs and major cardiovascular outcomes is crucial for therapeutic development.
Purpose of the Study:
- To explore the associations between genetically predicted circulating levels of various interleukins and the risk of coronary artery disease (CAD), atrial fibrillation (AF), and ischemic stroke.
- To elucidate the specific causal roles of different ILs in cardiovascular disease development.
Main Methods:
- A Mendelian randomization study design was employed.
- Genome-wide association studies identified single-nucleotide polymorphisms (SNPs) associated with IL-1β, IL-1 receptor antagonist (IL-1ra), IL-2 receptor subunit alpha, IL-6, IL-16, IL-17, and IL-18.
- Summary-level genetic data from large consortia were used for outcome association analyses.
Main Results:
- Genetically elevated IL-1ra levels showed a significant association with increased CAD risk (OR=1.36).
- Genetically elevated IL-6 levels, particularly those associated with reduced bio-function, were inversely associated with CAD (OR=0.64) and AF (OR=0.70).
- Suggestive associations were observed for IL-1ra with cardioembolic stroke and IL-6 with various ischemic stroke subtypes; IL-16 showed a suggestive inverse association with CAD.
Conclusions:
- Findings support IL-6 inhibition as a potential therapeutic strategy for preventing CAD, AF, and ischemic stroke.
- Elevated IL-1ra levels suggest a potential increased risk for CAD and cardioembolic stroke, indicating a possible detrimental role of IL-1 pathway activation.
- The association of IL-16 with CAD warrants further investigation.
Background:
The causal role of interleukins (ILs) for cardiovascular disease has not been fully elucidated. We conducted a Mendelian randomization study to investigate the associations of circulating ILs with coronary artery disease (CAD), atrial fibrillation (AF), and ischemic stroke.
Methods And Results:
Single-nucleotide polymorphisms associated with IL-1β, IL-1 receptor antagonist (IL-1ra), IL-2 receptor subunit alpha, IL-6, IL-16, IL-17 and IL-18 were identified from genome-wide association studies. Summary-level data of the outcomes were obtained from three large consortia. Genetic predisposition to higher IL-1ra levels were significantly associated with CAD. The odds ratio was 1.36 (95% confidence interval (CI), 1.14-1.63; P = 5.37 × 10-4) per one standard deviation increase in IL-1ra levels. Genetically higher IL-6 levels, predicted by a variant in the IL6R gene and corresponding to reduced IL-6 bio-function, were significantly inversely associated with CAD and AF. The odds ratios per one standard deviation increase in IL-6 levels were 0.64 (95%CI, 0.54-0.76; P = 2.22 × 10-7) for CAD and 0.70 (95%CI, 0.62-0.80; P = 1.34 × 10-7) for AF. There was a suggestive positive association of IL-1ra with cardioembolic stroke and suggestive inverse associations of IL-6 with any ischemic stroke, cardioembolic stroke, and small vessel stroke, and of IL-16 with CAD. The other ILs were not associated with any outcome.
Conclusions:
These results strengthen the evidence that IL-6 inhibition may offer a therapeutic approach for prevention of CAD, AF, and ischemic stroke. In contrast, IL-1 inhibition through raised IL-1ra levels may confer increased risk of CAD and cardioembolic stroke. The role of IL-16 for CAD warrants further investigation.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis I: Introduction
Acute Coronary Syndrome I: Introduction

